FDA Recalls Brilliant Blue G due to Reports of Severe Eye Infections

- by

Washington, DC: The Centers for Disease Control and Prevention (CDC) is advising healthcare personnel to avoid use of compounded products labeled as sterile from Franck' while an investigation by the Food and Drug Administration (FDA) is underway.

The FDA has issued a second warning to physicians regarding certain compounded drugs from Franck's. The FDA received reports of eye infections in patients who were given injections of drug products containing triamcinolone during eye surgery.

The BBG was supplied by Franck' Compounding Lab, Ocala, Florida. Franck' Pharmacy issued a recall on March 9, 2012, of all lots of Brilliant Blue G and issued a recall letter. Brilliant Blue G is not an approved drug in the U.S. The Food and Drug Administration (FDA) has received reports of fungal endophthalmitis (eye infections) in patients who were given Brilliant Blue G (BBG) during eye surgeries.

Clinicians in several states reported the adverse events. FDA, along with Centers for Disease Control (CDC) and local and state public health agencies, are actively investigating these adverse events.

Legal Help

If you or a loved one has suffered illness, injury or damages in this case, please fill in our form on the right and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.
Last updated May 4 2012

Add Your Comment on This Issue

Please read our comment guidelines before posting.

Note: Your name will be published with your comment.

Your email will only be used if a response is needed.

Request Legal Help